The National Institute on Drug Abuse (NIDA), has awarded a 5 year base contract to Bridge Laboratories for the amount of $4.1 million. Bridge will be providing Toxicological Evaluation services on potential medicine for the treatment of drug abuse. Bridge Laboratories is a CRO that services globally, but is based out of the U.S. in Maryland with lab facilities in Beijing, China. As reported in this article, the CEO and President, Tom Oakley released this statement.
“We appreciate the confidence NIDA has shown in Bridge Laboratories over the past five years and look forward to collaborating with them to find ways to significantly improve prevention, treatment, and policy as it relates to drug abuse and addiction”
Search This Blog
Blog Archive
-
▼
2008
(97)
-
▼
October
(16)
- India possibility for Australia's CROs Needs
- CRO Stock Prices Going Down
- CROs Open New Opportunities for Employment
- Clinical Outsourcing Spend is Going Down
- Reducing Costs and Time of Cancer Trials
- Pharma Companies Are Outsourcing Less of Clinical ...
- Are companies budgeting less towards their outsour...
- Averion expands in Eastern Europe
- New report focusing on outsourcing in central Europe
- ethica Clinical Research expands to South America
- Clincal Trials in India
- Clinical Trials Today: ethica Heads to South America
- Bridge Laboratories to Support NIDA
- Changing Face of CRO's
- Update to China’s Growing Lead in Clinical Outsour...
- China is Ahead of India in Outsourced Trials
-
▼
October
(16)
No comments:
Post a Comment